Drug Profile
TAK 233
Alternative Names: OP-233; TAK-233Latest Information Update: 22 Nov 2017
Price :
$50
*
At a glance
- Originator Takeda
- Developer Outpost Medicine
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Stress incontinence
Most Recent Events
- 22 Nov 2017 9227177-updated intro, KDM, dev dis, updated dev table
- 15 Nov 2017 Discontinued - Phase-I for Stress incontinence (In volunteers, In adults) in Japan (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Stress-incontinence(In volunteers, In adults) in Japan (PO)